MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

CVS Caremark will stop covering Eli Lilly’s Zepbound. Wegovy, the GLP-1 medication to treat obesity from Lilly competitor ...

Novo Nordisk is in the lead, but not alone. Obesity doctors say they are gearing up for demand, predicted to be high. Some ...

GLP-1 drugs currently being tested in China target complications associated with obesity such as heart disease, fatty liver ...

A new study reveals that weight lost with GLP-1 drugs, such as semaglutide, is regained within a year after stopping ...

Experts are warning anyone experiencing GLP-1 drug side effects to report them after launching an investigation into their safety.

A study in Diabetes, Obesity and Metabolism has identified certain characteristics that might influence people's weight loss ...

Study finds the GLP-1 drug liraglutide reduced migraine days by almost 50% in patients with obesity, with quality of life ...

Eli Lilly’s Zepbound transformed weight loss drug market since debut 18 months ago 4.5 million people reportedly taking Lilly ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs ...

According to the CDC, 1 in 5 American adults is living with obesity. In recent years, many have turned to weight loss drugs containing GLP-1, a hormone that slows digestion and helps with ...